Loading company filing…
Find a company. Follow its revenue through costs and profit.
Coverage includes separate ticker and security records; counts are not unique companies.
Sankey diagram of Solasia Pharma K.K.. A complete text table follows the diagram.
Only JPY49 million of revenue supported JPY232 million of R&D across a pipeline spanning oral-care, neuropathy and cancer therapies.
Swipe to explore
Every category amount is a reported EDINET XBRL fact. Nodes described as arithmetic bridges are calculated residuals and do not imply a separately reported filing line.
Labels and narrative explain the filing. A category marked “arithmetic bridge” or “residual” is calculated from reported totals, rather than a separately reported line.
| Category | Stage | Value | Notes |
|---|---|---|---|
| Early-stage oncology product sales | 1 | 49M | 100.0% of reported total |
| Revenue | 2 | 49M | Reported six-month total · ¥49M |
| Operating loss | 2 | 537M | Absolute value of reported operating loss |
| Operating costs & expenses | 3 | 586M | Revenue plus reported operating loss |
| From | To | Value |
|---|---|---|
| Early-stage oncology product sales | Revenue | 49M |
| Revenue | Operating costs & expenses | 49M |
| Operating loss | Operating costs & expenses | 537M |